BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.0x | −2.0x | −0.5x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 0.8x | 2.4x | 2.6x | |
Price / LTM Sales | 0.9x | 7.7x | 3.3x | |
Upside (Analyst Target) | - | 400.0% | 40.1% | |
Fair Value Upside | Unlock | 20.0% | 5.1% | Unlock |